ALLOSTEROS THERAPEUTICS, INC. — Department of Health and Human Services SBIR Phase I: 200

Description

Type diabetes mellitus has become a worldwide epidemic with significant human and economic burdens Diabetic patients are particularly at risk of mortality from myocardial infarction and it is therefore important that glucose lowering is achieved by drugs that do not further compromise the heart Evidence now supports Ca calmodulin dependent protein kinase II CaMKII a mediator Ca signaling in liver and heart as a novel target for inhibitors with the unique dual action of lowering glucose while providing cardioprotection Genetic approaches have rigorously demonstrated that a CaMKII p a MK pathway mediates the action of glucagon on glucose production in liver while a CaMKII Ryanodine receptor pathway underlies dysregulated Ca signaling in heart Genetic suppression of CaMKII lowers blood glucose and decreases progression from hypertrophy to heart failure and arrhythmia while its hyperactivity increases blood glucose and promotes heart disease We propose to advance our highly selective allosteric small molecule CaMKII inhibitors via lead optimization and test the feasibility that they lower hepatic glucose production Activated CaMKII is prone to pathological hyperactive states in diabetes due to oxidation and other post translational modifications all of which are blocked by our allosteric inhibitors We propose a structure based medicinal chemistry strategy of lead optimization to increase inhibitor potency and limit any CNS penetration while retaining their high kinase selectivity We will evaluate their biochemical and cellular properties to ensure they have the desired characteristics prior to a mechanistic POC in lowering hepatic glucose output in ob ob mice Successful completion of our Phase I milestones will set a clear path for a Phase II proposal to further advance its pharmacokinetics and other drug like properties and extend the proof of concept for cardioprotection and long term glucose control Pharma and venture capitalists have shown significant interest in our allosteric CaMKII inhibitor program their funding is dependent on achieving a more advanced lead compound that does not affect brain CaMKII while showing preclinical efficacy in glucose control Our proposed studies and an SBIR award will position the program for funding or a partnership to advance through IND enabling studies and an IND Diabetes has become a worldwide epidemic that is affecting more than million people in the U S High glucose seen in patients with diabetes and with obesity leads to long term complications and greatly increases mortality following a heart attack Evidence now supports a therapeutic approach based on blocking the hyperactivity of a signaling molecule termed Ca calmodulin dependent protein kinase II that will both reduce the production of glucose by the liver and reduce the poor cardiovascular outcomes Our aim is therefore to optimize an inhibitor of this kinase and test its ability to lower blood glucose in a diabetes model as a proof of concept